Sunscreen monograph
This article was originally published in The Rose Sheet
Executive Summary
FDA should "move up" anticipated implementation date so standards take effect before 2005, American Academy of Dermatology Association says in April 1 comments. "Proceedings of the UVA consensus conference, summarized in the AADA policy, represent a body of immediately accessible knowledge that should be tapped" and should "substantially shorten the amount of time needed" for FDA to draft a sunscreen monograph amendment, group says. Agency, which postponed Dec. 31, 2002 implementation date to create a comprehensive amendment addressing UVA protection, does not expect a new effective date prior to January 2005 (1"The Rose Sheet" Jan. 7, 2002, p. 3). AADA, Skin Cancer Foundation also urge FDA to remove monograph's SPF "30-plus" cap on labeling...
You may also be interested in...
Sunscreen Monograph Effective Date Extended To Address UVA Standards
The Dec. 31, 2002 implementation date of the OTC sunscreen final monograph has been postponed until further notice for the majority of sunscreens, the agency announces in a 11Dec. 31 Federal Register notice
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.